AR088226A1 - Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas - Google Patents
Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativasInfo
- Publication number
- AR088226A1 AR088226A1 ARP120103691A ARP120103691A AR088226A1 AR 088226 A1 AR088226 A1 AR 088226A1 AR P120103691 A ARP120103691 A AR P120103691A AR P120103691 A ARP120103691 A AR P120103691A AR 088226 A1 AR088226 A1 AR 088226A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- heterociclic
- treatment
- pharmaceutical compositions
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto representado por la fórmula (1) caracterizado porque R¹ es un grupo alquilo C₁₋₆ opcionalmente sustituido; R² es un átomo de hidrógeno o un grupo alquilo C₁₋₆ opcionalmente sustituido; R³ es un grupo heterocíclico aromático de 5 ó 6 miembros opcionalmente sustituido; anillo A es un anillo piperidina también opcionalmente sustituido (el anillo piperidina está opcionalmente en puente); y anillo B es un anillo aromático de 5 ó 6 miembros también opcionalmente sustituido (X e Y son, de modo independiente, un átomo de carbono o un átomo de nitrógeno); o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011222741 | 2011-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088226A1 true AR088226A1 (es) | 2014-05-21 |
Family
ID=47143241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103691A AR088226A1 (es) | 2011-10-07 | 2012-10-03 | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas |
Country Status (41)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX360706B (es) | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
| WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11201504516PA (en) | 2012-12-11 | 2015-07-30 | Takeda Pharmaceutical | Heterocyclic compound |
| ES2886506T3 (es) | 2013-03-13 | 2021-12-20 | Sage Therapeutics Inc | Esteroides neuroactivos |
| US9598398B2 (en) | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2014163162A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015190613A1 (en) | 2014-06-09 | 2015-12-17 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
| CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
| MA54851A (fr) | 2015-07-06 | 2021-12-08 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| WO2017065287A1 (ja) * | 2015-10-16 | 2017-04-20 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| PT3436022T (pt) | 2016-04-01 | 2022-07-04 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JPWO2017195894A1 (ja) * | 2016-05-13 | 2019-03-14 | 日産化学株式会社 | ２−アセチルピリジン化合物の製造方法 |
| BR112019006365A2 (pt) | 2016-09-30 | 2019-08-06 | Sage Therapeutics Inc | oxisteróis substituídos c7 e métodos de utilização dos mesmos |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CN116370475A (zh) * | 2017-08-31 | 2023-07-04 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| WO2020027344A1 (en) | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
| US20210346366A1 (en) * | 2018-09-20 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for pain use |
| JP7189749B2 (ja) | 2018-12-04 | 2022-12-14 | 株式会社日立産機システム | スクリュー圧縮機 |
| TW202110824A (zh) * | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| JP2023550654A (ja) * | 2020-11-25 | 2023-12-04 | セージ セラピューティクス， インコーポレイテッド | 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 |
| WO2022261510A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| ATE298765T1 (de) | 1996-08-27 | 2005-07-15 | Praecis Pharm Inc | Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren |
| CN1379819A (zh) | 1999-06-28 | 2002-11-13 | 俄克拉荷马州医学研究基金会 | 具有催化活性的重组memapsin蛋白酶及其应用方法 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| AU2002248432A1 (en) | 2001-02-14 | 2002-08-28 | Sankyo Company, Limited | Oxazole derivatives, their preparation and their use as cytokine inhibitors |
| CA2445568A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| DOP2005000039A (es) | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| WO2006137465A1 (ja) | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | 含窒素複素環誘導体 |
| EP1957479B1 (en) | 2005-11-30 | 2011-03-02 | F. Hoffmann-La Roche AG | 1,5-substituted indol-2-yl amide derivatives |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| WO2008134547A1 (en) * | 2007-04-25 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions |
| WO2008153722A1 (en) | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| EP2367812B1 (en) | 2008-08-22 | 2015-09-16 | Sanofi | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4trifluoromethoxy-1h-indol-3-yl]methanone as an inhibitor of mast cell tryptase |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| DE102009022896A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022894A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| JP5316468B2 (ja) | 2010-04-09 | 2013-10-16 | 株式会社豊田自動織機 | リアクトル構造 |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| MX360706B (es) * | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
-
2012
- 2012-10-03 MX MX2014004253A patent/MX360706B/es active IP Right Grant
- 2012-10-03 AR ARP120103691A patent/AR088226A1/es active IP Right Grant
- 2012-10-03 ES ES12781479T patent/ES2716531T3/es active Active
- 2012-10-03 AP AP2014007606A patent/AP2014007606A0/xx unknown
- 2012-10-03 UY UY0001034365A patent/UY34365A/es not_active Application Discontinuation
- 2012-10-03 AU AU2012321815A patent/AU2012321815B2/en active Active
- 2012-10-03 WO PCT/JP2012/076257 patent/WO2013054822A1/en active Application Filing
- 2012-10-03 ME MEP-2019-69A patent/ME03372B/me unknown
- 2012-10-03 UA UAA201404855A patent/UA115133C2/uk unknown
- 2012-10-03 US US14/349,201 patent/US9193709B2/en active Active
- 2012-10-03 PL PL12781479T patent/PL2763979T3/pl unknown
- 2012-10-03 PE PE2014000466A patent/PE20141120A1/es active IP Right Grant
- 2012-10-03 BR BR122022001219-1A patent/BR122022001219B1/pt active IP Right Grant
- 2012-10-03 DK DK12781479.6T patent/DK2763979T3/en active
- 2012-10-03 BR BR112014007257-4A patent/BR112014007257B1/pt active IP Right Grant
- 2012-10-03 TR TR2019/02788T patent/TR201902788T4/tr unknown
- 2012-10-03 PT PT12781479T patent/PT2763979T/pt unknown
- 2012-10-03 SG SG2014010417A patent/SG2014010417A/en unknown
- 2012-10-03 GE GEAP201213457A patent/GEP201706608B/en unknown
- 2012-10-03 HU HUE12781479A patent/HUE043171T2/hu unknown
- 2012-10-03 JP JP2014513813A patent/JP6117191B2/ja active Active
- 2012-10-03 TW TW101136475A patent/TWI582084B/zh active
- 2012-10-03 RS RS20190304A patent/RS58470B1/sr unknown
- 2012-10-03 MY MYPI2014700836A patent/MY176126A/en unknown
- 2012-10-03 LT LTEP12781479.6T patent/LT2763979T/lt unknown
- 2012-10-03 SI SI201231548T patent/SI2763979T1/sl unknown
- 2012-10-03 EA EA201490747A patent/EA025662B1/ru not_active IP Right Cessation
- 2012-10-03 CA CA2851087A patent/CA2851087C/en active Active
- 2012-10-03 KR KR1020147011963A patent/KR101967497B1/ko active IP Right Grant
- 2012-10-03 CN CN201280049068.8A patent/CN103842356B/zh active Active
- 2012-10-03 EP EP12781479.6A patent/EP2763979B1/en active Active
- 2012-10-03 US US13/633,995 patent/US8648079B2/en active Active
-
2013
- 2013-07-17 US US13/944,000 patent/US8865717B2/en active Active
- 2013-07-17 US US13/944,042 patent/US8871766B2/en active Active
-
2014
- 2014-03-24 IL IL231678A patent/IL231678A/en active IP Right Grant
- 2014-03-25 TN TNP2014000122A patent/TN2014000122A1/en unknown
- 2014-04-02 ZA ZA2014/02424A patent/ZA201402424B/en unknown
- 2014-04-02 CL CL2014000806A patent/CL2014000806A1/es unknown
- 2014-04-03 CR CR20140151A patent/CR20140151A/es unknown
- 2014-04-04 DO DO2014000064A patent/DOP2014000064A/es unknown
- 2014-04-29 EC ECSP14013329 patent/ECSP14013329A/es unknown
- 2014-05-02 CO CO14094354A patent/CO6940432A2/es unknown
- 2014-05-04 MA MA36973A patent/MA35623B1/fr unknown
-
2015
- 2015-09-08 US US14/847,703 patent/US9440990B2/en active Active
-
2016
- 2016-07-28 US US15/221,761 patent/US9586930B2/en active Active
-
2017
- 2017-02-03 US US15/424,075 patent/US10144743B2/en active Active
-
2018
- 2018-11-19 US US16/194,540 patent/US10273245B2/en active Active
-
2019
- 2019-03-12 HR HRP20190491TT patent/HRP20190491T1/hr unknown
- 2019-03-18 CY CY20191100324T patent/CY1121549T1/el unknown
- 2019-04-11 US US16/381,163 patent/US10550129B2/en active Active
-
2020
- 2020-02-03 US US16/779,797 patent/US10717748B2/en active Active
- 2020-07-20 US US16/933,092 patent/US11174272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| ECSP14020586A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| CO7141456A2 (es) | Derivados de aril-sultamo como moduladores de rorc | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| AR084032A1 (es) | Compuesto biciclico | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2012000318A (es) | Compuestos heterociclicos fusionados | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| NI201200095A (es) | Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica | |
| ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos | |
| AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b | |
| AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |